| Qualitative criteria: Image, Company reputation, Dialogue with stakeholders | Weighting 7.5% |
|---|---|
|
Interview with Luca de Meo in Le Figaro on the announcement of the acquisition of Kering Beauté and the creation of an exclusive joint venture in Longevity.
|
|
|
|
Pursuant in particular to Articles L. 225-197-1 and L. 22-10-8 of the French Commercial Code and the authorisation of the General Meeting of 23 April 2024, the Board of Directors meeting on 10 October 2025, taking into account the performance of Nicolas Hieronimus and the share price valuation, decided to grant him 20,000 performance shares (ACAs – Attributions Conditionnelles d'Actions, existing conditional grants of shares), in accordance with the remuneration policy. Based on the IFRS used to prepare the consolidated financial statements, the estimated fair value of one performance share (ACAs) for the 10 October 2025 plan, of which Nicolas Hieronimus is a beneficiary, is €348.48.
The estimated fair value, based on IFRS valuations, of the 20,000 performance shares (ACAs) granted in 2025 to Nicolas Hieronimus is therefore €6,969,600.
These shares will only vest, in whole or in part, once the performance conditions described below are met(1).